NeuroDerm (NDRM) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to NeuroDerm (NDRM) Misses Q2 EPS by 14c
August 6, 2015 7:00 AM EDT
REHOVOT, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2015 and provided a corporate update.
"We recently closed a successful public offering that increased the Company's cash position significantly, allowing us the necessary funds to pursue our activities and expand their scope. We are also pleased that our head-to-head pilot pharmacokinetic study in Europe comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an... More
August 6, 2015 7:00 AM EDT
REHOVOT, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2015 and provided a corporate update.
"We recently closed a successful public offering that increased the Company's cash position significantly, allowing us the necessary funds to pursue our activities and expand their scope. We are also pleased that our head-to-head pilot pharmacokinetic study in Europe comparing ND0612H, our subcutaneously delivered high dose product candidate for advanced Parkinson's disease, with Duodopa®, an... More
